High Metabolic Tumour Volume on 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Poor Survival from Neuroendocrine Neoplasms

被引:21
作者
Chan, David L. [1 ,2 ,3 ,4 ]
Bernard, Elizabeth J. [1 ]
Schembri, Geoffrey [1 ]
Roach, Paul J. [1 ]
Johnson, Meaghan [1 ]
Pavlakis, Nick [2 ,3 ]
Clarke, Stephen [2 ,3 ]
Bailey, Dale L. [1 ,4 ]
机构
[1] Royal North Shore Hosp, Dept Nucl Med, St Leonards, NSW, Australia
[2] Royal North Shore Hosp, Dept Med Oncol, St Leonards, NSW, Australia
[3] Univ Sydney, Kolling Inst, Bill Walsh Translat Canc Res Lab, Sydney, NSW, Australia
[4] Sydney Vital Translat Canc Res Ctr, Sydney, NSW, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
Neuroendocrine neoplasm; Prognosis; Positron emission tomography; F-18-FDG PET/CT; CANCER; PARAMETERS; INDEX;
D O I
10.1159/000504673
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction:18-Fluorodeoxyglucose (F-18-FDG) positron emission tomography (PET) avidity in neuroendocrine neoplasms (NENs) has been associated with higher-grade disease. F-18-FDG avidity and high SUVmax have been demonstrated to predict poor outcome. Quantitative metrics of F-18-FDG PET, specifically metabolic tumour volume (MTV) and total lesion glycolysis (TLG), have been shown to be prognostic factors in other malignancies, but these have not been investigated to date in NENs.Methods:Patients with NEN undergoing F-18-FDG at Royal North Shore Hospital from 2012 to 2018 were included. Images were analysed with automated segmentation (SUV cut-off of 4) followed by contour verification by a nuclear medicine physician and manual segmentation where required. Variables collected included patient age, histological grade, MTV, TLG, and SUVmax/SUVmean. The primary outcome was overall survival (OS), and the secondary outcome was progression-free survival (PFS). Univariate (UV) and multivariate (MV) analyses were performed for OS and PFS for MTV and TLG separately. For UV analysis, the median MTV and TLG were used to dichotomise the cohort. MTV/TLG for NENs of different histological grade were compared using ANOVA.Results:One hundred and ninety patients were included (median age 63.5, 49% female). Primary site: 42% small bowel, 32% pancreas, 15% other gastrointestinal, 6% lung, 6% other. Grade for gastroenteropancreatic NENs and bronchial NEN: G1/typical carcinoid 37%, G2/atypical carcinoid 40%, G3/large-cell/small-cell neuroendocrine carcinoma 16%, unknown 8%. Median MTV was 4.83 mL (range 0-3,161 mL) and median TLG was 29.22. Patients with high MTV had worse median OS compared to those with low MTV (29.7 months vs. not reached, HR 4.1, 95% CI 2.25-7.49,p< 0.00001). Considered as a continuous variable, MTV predicted for poorer OS on UV (p< 0.00001) and MV (p= 0.003) analyses. Whilst histological grade was significant on both UV and MV, SUVmax was significant on UV (p< 0.00001) but not MV (p= 0.76). Tumours of higher grade had higher MTV (mean MTV - G1: 39.6 mL, G2: 107 mL, G3: 337 mL;p= 0.0001 by ANOVA).Conclusions:Quantitative analysis of F-18-FDG PET in NEN is feasible. High MTV/TLG are predictors of poor prognosis in NEN. Further analyses are underway to investigate a larger cohort of NEN patients.
引用
收藏
页码:950 / 958
页数:9
相关论文
共 22 条
[1]  
[Anonymous], 2010, WHO CLASSIF TUMOURS
[2]   High Prognostic Value of 18F-FDG PET for Metastatic Gastroenteropancreatic Neuro endocrine Tumors: A Long-Term Evaluation [J].
Bahri, Haifa ;
Laurence, Lenoir ;
Edeine, Julien ;
Leghzali, Houda ;
Devillers, Anne ;
Raoul, Jean-Luc ;
Cuggia, Marc ;
Mesbah, Habiba ;
Clement, Bruno ;
Boucher, Eveline ;
Garin, Etienne .
JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (11) :1786-1790
[3]   Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PET [J].
Binderup, Tina ;
Knigge, Ulrich ;
Loft, Annika ;
Mortensen, Jann ;
Pfeifer, Andreas ;
Federspiel, Birgitte ;
Hansen, Carsten Palnaes ;
Hojgaard, Liselotte ;
Kjaer, Andreas .
JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (05) :704-712
[4]   18F-FDG Uptake in Well-Differentiated Neuroendocrine Tumors Correlates with Both Ki-67 and VHL Pathway Inactivation [J].
Bucau, Margot ;
Laurent-Bellue, Astrid ;
Pote, Nicolas ;
Hentic, Olivia ;
Cros, Jerome ;
Mikail, Nidaa ;
Rebours, Vinciane ;
Ruszniewski, Philippe ;
Lebtahi, Rachida ;
Couvelard, Anne .
NEUROENDOCRINOLOGY, 2018, 106 (03) :274-282
[5]   Standardized Uptake Values of 68Ga-DOTANOC PET: A Promising Prognostic Tool in Neuroendocrine Tumors [J].
Campana, Davide ;
Ambrosini, Valentina ;
Pezzilli, Raffaele ;
Fanti, Stefano ;
Labate, Antonio Maria Morselli ;
Santini, Donatella ;
Ceccarelli, Claudio ;
Nori, Francesca ;
Franchi, Roberto ;
Corinaldesi, Roberto ;
Tomassetti, Paola .
JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (03) :353-359
[6]   Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance [J].
Chan, David L. H. ;
Pavlakis, Nick ;
Schembri, Geoffrey P. ;
Bernard, Elizabeth J. ;
Hsiao, Edward ;
Hayes, Aimee ;
Barnes, Tristan ;
Diakos, Connie ;
Khasraw, Mustafa ;
Samra, Jaswinder ;
Eslick, Enid ;
Roach, Paul J. ;
Engel, Alexander ;
Clarke, Stephen J. ;
Bailey, Dale L. .
THERANOSTICS, 2017, 7 (05) :1149-1158
[7]   Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States [J].
Dasari, Arvind ;
Shen, Chan ;
Halperin, Daniel ;
Zhao, Bo ;
Zhou, Shouhao ;
Xu, Ying ;
Shih, Tina ;
Yao, James C. .
JAMA ONCOLOGY, 2017, 3 (10) :1335-1342
[8]   Cancer patient preferences for communication of prognosis in the metastatic setting [J].
Hagerty, RG ;
Butow, PN ;
Ellis, PA ;
Lobb, EA ;
Pendlebury, S ;
Leighl, N ;
Goldstein, D ;
Lo, SK ;
Tattersall, MHN .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1721-1730
[9]   Exploring the Rising Incidence of Neuroendocrine Tumors: A Population-Based Analysis of Epidemiology, Metastatic Presentation, and Outcomes [J].
Hallet, Julie ;
Law, Calvin How Lim ;
Cukier, Moises ;
Saskin, Refik ;
Liu, Ning ;
Singh, Simron .
CANCER, 2015, 121 (04) :589-597
[10]  
Jo HJ, 2014, CLIN NUCL MED, V39, P493, DOI 10.1097/RLU.0000000000000438